Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Dec 31, 2022 1:46pm
89 Views
Post# 35198513

RE:RE:RE:RE:RE:RE:Midatech at $1.0475

RE:RE:RE:RE:RE:RE:Midatech at $1.0475"Question is , is someone else going to give us a better offer soon or was/is this the best offer possible given the market conditions?"

That's one question...
No one else has stepped up yet although there is still time.
That will play out.

Another question, what is the upside of Biodexa given its cash runway to key catalysts over the next 18 months, etc., and its considerable asset base? The dilution comes with upside. Biodexa's CEO has talked about very rare upside. Not many here care.

I wonder if a major limiting factor for BTI this past decade has been its shareholder base? It has been said that Rathjen was asked to swear off dilution. To avoid major dilution that would address BTI's undercapitalization and advance its science BTI has lived hand-to-mouth financially for a decade racking up massive dilution regardless and getting nowhere. Shareholders have been like the boiling frog slowly being diluted to death with no scientific advancement as they walk into the worst biotech market in history. Shareholders didn't mind as long as immediate dilution was avoided. BTI even took on significant debt to avoid immediate dilution further exposing itself to the risk of massive dilution. By obsessivly fearing dilution so much BTI has been slow-walked into catastrophic dilution. They have manifested their fear.

Rathjen is trying to break this cycle by decisively acting during an incredibly difficult time in the market and by creating upside. One can't just fear dilution to escape. One must also embrace the risk to upside.



"Do You Attract What You Fear?"

"You may have big dreams and have great intentions to attract and manifest certain things but you end up attracting something that is often the opposite."
 
 
<< Previous
Bullboard Posts
Next >>